HCC- and HCC+CC-derived models pair culture morphology, H&E and lineage-related IHC to guide efficacy and mechanism endpoints.
STUDY EVIDENCE
HCC- and HCC+CC-derived model figures combine culture morphology, histology and immunohistochemistry to establish model context and guide endpoint selection for follow-on efficacy and mechanism studies.
PDO culture morphology is evaluated with source-tissue/PDO H&E and endothelial- and hepatocyte-related IHC to connect culture, tissue structure and lineage context.
Guides model and endpoint selection for efficacy and mechanism studies
Bright-field and whole-mount immunofluorescence in a conventional HCC PDO document morphology and cell state, adding a complementary conventional-PDO view to liver-cancer study design.
Adds conventional-PDO morphology and cell-state contextINTERPRETATION
Defines efficacy or mechanism study directions for the profiled liver-tumor samples.
Interpret results in the context of sample pathology, tissue source, culture morphology and markers, then use them to design efficacy and mechanism studies.
Build pathology- and target-informed dose, time-course and additional-sample studies.
Related models and services
PROJECT DISCUSSION
Tell us which model features and readouts matter most. Our scientists will recommend the model, QC plan and study endpoints.
HCC- and HCC+CC-derived models pair culture morphology, H&E and lineage-related IHC to guide efficacy and mechanism endpoints.
STUDY EVIDENCE
HCC- and HCC+CC-derived model figures combine culture morphology, histology and immunohistochemistry to establish model context and guide endpoint selection for follow-on efficacy and mechanism studies.
PDO culture morphology is evaluated with source-tissue/PDO H&E and endothelial- and hepatocyte-related IHC to connect culture, tissue structure and lineage context.
Guides model and endpoint selection for efficacy and mechanism studiesBright-field and whole-mount immunofluorescence in a conventional HCC PDO document morphology and cell state, adding a complementary conventional-PDO view to liver-cancer study design.
Adds conventional-PDO morphology and cell-state contextINTERPRETATION
Defines efficacy or mechanism study directions for the profiled liver-tumor samples.
Interpret results in the context of sample pathology, tissue source, culture morphology and markers, then use them to design efficacy and mechanism studies.
Build pathology- and target-informed dose, time-course and additional-sample studies.
Related models and services
PROJECT DISCUSSION
Tell us which model features and readouts matter most. Our scientists will recommend the model, QC plan and study endpoints.
